Review
Chemistry, Medicinal
Ranju Bansal, Anjleena Malhotra
Summary: Cancer is a serious health issue with available chemotherapeutic drugs being highly toxic and lacking selectivity. Advances in science have illuminated molecular pathways responsible for cancer, leading to the development of targeted anticancer agents, such as quinazoline derivatives. These agents act by inhibiting various protein kinases and other molecular targets, offering new opportunities for more effective cancer treatment.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Pharmacology & Pharmacy
Joanna Kurczewska
Summary: This review focuses on the progress in chitosan-based nanoparticles for targeted delivery of antitumor drugs. It discusses literature reports from the past three years on the use of chitosan nanoparticles as carriers for active substances in antitumor therapy and potential new drugs with anticancer properties. Special attention is given to different treatments applied to enhance therapeutic effectiveness and minimize side effects of specific active substances.
Review
Medicine, Research & Experimental
Yan-Nan Chi, Jia-Mei Yang, Ning Liu, Yan-Hong Cui, Lin Ma, Xiao-Bing Lan, Wen-Qian Ma, Yan-Jie Liu, Jian-Qiang Yu, Juan Du
Summary: Chemotherapeutic agents can cause death or activation acceleration of follicles and damage to blood vessels in the ovary, resulting in inflammation. There is a need for the development of drugs to protect the ovaries from injury. Although there are many preclinical studies on potential protective drugs, more clinical experiments are urgently needed to verify their potential use.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Chemistry, Inorganic & Nuclear
Maonan Wang, Jingzhou Zhao, Hongjie Xiong, Hongbing Lu, Hui Jiang, Xuemei Wang
Summary: Tumor-associated macrophages (TAM) play a crucial role in promoting tumor growth, stimulating angiogenesis, and inhibiting the immune response. Understanding the specific role of TAM in immune escape is essential for evaluating targeted TAM therapies in the clinic. This article reviews how TAM can influence different immune cells, macrophage polarization, and the use of nano-drugs targeting TAMs, providing promising platforms for the effective treatment of various clinical immune targets in tumors.
COORDINATION CHEMISTRY REVIEWS
(2021)
Review
Oncology
Duoli Xie, Zhuqian Wang, Jie Li, De-an Guo, Aiping Lu, Chao Liang
Summary: Osteosarcoma is an aggressive bone cancer with unknown molecular pathways, making it difficult to improve patient survival. Conventional therapies have severe side effects due to the lack of selectivity for malignant tissue. Researchers are exploring targeted treatment methods by combining specific ligands and chemotherapeutic agents to treat tumor cells.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Soumiya Pal, Jenat Rahman, Shengyu Mu, Nancy J. Rusch, Amanda J. Stolarz
Summary: The lymphatic circulation is crucial for the transport of lymph fluid, but certain medications may disrupt lymph flow and contribute to the development of lymphedema. This review examines the potential mechanisms of drug-related lymphedema, with a focus on common medications used for cardiovascular diseases, metabolic disorders, and cancer. It also explores possible therapeutic options for lymphedema.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Chemistry, Medicinal
Yu Peng, Hongxun Tao, Yuanqing Gao, Yuanyuan Yang, Zhiyong Chen
Summary: With the increasing prevalence of cancer, the development of tissue-agnostic targeted therapy based on biological characteristics has become a breakthrough in precision oncology, offering broad-spectrum anticancer significance.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Inorganic & Nuclear
Alexander Kastner, Theresa Mendrina, Florian Bachmann, Walter Berger, Bernhard K. Keppler, Petra Heffeter, Christian R. Kowol
Summary: In this study, oxaliplatin(iv)-based complexes were developed as platinum(iv) prodrugs to release aspirin, which has shown antitumor activity against colon cancer. The newly synthesized complex demonstrated increased reduction stability compared to a cisplatin analog and exhibited desired prodrug properties in cell culture. A derivative with albumin-binding properties showed improved pharmacokinetics and tumor accumulation, leading to enhanced antitumor activity and overall survival in tumor-bearing mice.
INORGANIC CHEMISTRY FRONTIERS
(2023)
Article
Oncology
Alexandre Crosnier, Chadi Abbara, Morgane Cellier, Laurence Lagarce, Marina Babin, Delphine Bourneau-Martin, Marie Briet
Summary: This study found that the renal toxicity of anti-EGFR drugs is primarily related to renal failure in the context of digestive toxicity. Signals of disproportionate reporting were observed for afatinib and erlotinib with acute kidney injury, and for afatinib, cetuximab, and erlotinib with renal failure. Additionally, erlotinib was associated with haemolytic and uremic syndrome and thrombotic microangiopathy.
Review
Nutrition & Dietetics
Suzy Salama, Qiyang Shou, Aida A. Abd El-Wahed, Nizar Elias, Jianbo Xiao, Ahmed Swillam, Muhammad Umair, Zhiming Guo, Maria Daglia, Kai Wang, Shaden A. M. Khalifa, Hesham R. El-Seedi
Summary: Cancer is a major global cause of death. A healthy lifestyle, including a nutritious diet, is crucial in the treatment and prevention of cancer. Royal jelly, produced by young nurse honeybees, contains bioactive substances that have various beneficial effects, such as antioxidant, anticancer, and anti-inflammatory properties. Combining royal jelly with anticancer drugs can enhance their effectiveness or reduce side effects.
Article
Chemistry, Medicinal
Taiga Yamada, Teruyuki Komatsu
Summary: Photodynamic therapy (PDT) utilizes visible-light irradiation of photosensitizers (PSs) to induce apoptosis in tumors and microbial cells. However, macrocyclic compounds tend to agglutinate and lose photochemical activity in aqueous environments. Encapsulation within liposomes and polymer micelles can overcome this limitation. Hemoproteins and serum albumin have shown potential as hosts for porphyrin PS molecules. This concept paper provides a comprehensive review of recent developments and trends of protein-porphyrin complex PSs for anticancer and antimicrobial PDT applications.
Review
Cardiac & Cardiovascular Systems
Avirup Guha, Yan Gong, David DeRemer, Jocelyn Owusu-Guha, Susan F. Dent, Richard K. Cheng, Neal L. Weintraub, Neeraj Agarwal, Michael G. Fradley
Summary: Cardiometabolic disease is the most common preventable cause of death worldwide. This review focuses on the mechanistic and epidemiological evidence of cardiometabolic disease in four categories of anticancer medications. It emphasizes the importance of careful monitoring and the role of specialized healthcare professionals in managing patients at risk.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2022)
Review
Ophthalmology
Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, Marie Helene Errera, Hitesh Agrawal, Marco Lupidi, Jay Chhablani
Summary: Newer anticancer drugs have had a significant impact on cancer treatment in the past decade, but traditional chemotherapy remains important in many cases. Retinal toxicities associated with anticancer drugs can vary in severity, from mild anterior uveitis to more serious conditions like posterior uveitis and vascular occlusion. Understanding the mechanisms of toxicity is crucial in managing these complications and improving patient outcomes.
SURVEY OF OPHTHALMOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Sanne de Wit, Claire Glen, Rudolf A. de Boer, Ninian N. Lang
Summary: Heart failure and cancer have a bidirectional relationship, with patients with heart failure at increased risk for developing cancer and cancer presence leading to impaired cardiac function. Additionally, targeted anti-cancer therapies may also cause cardiac toxicity due to overlap between their targets and pathways required for normal cardiac function.
CARDIOVASCULAR RESEARCH
(2023)
Review
Dermatology
Jonathan K. Hwang, Jose W. Ricardo, Shari R. Lipner
Summary: This study provides an updated systematic review on targeted therapies for nail psoriasis, incorporating recent trials and newer agents. The results reveal significant efficacy of targeted therapies, especially TNF-alpha inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors. The newer agents brodalumab, risankizumab, and tildrakizumab also show promising outcomes for nail psoriasis treatment based on current data.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2023)
